These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24742867)

  • 1. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
    Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
    Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.
    Yuan X; Meng Y; Li P; Ge N; Kong F; Yang L; Björkholm M; Zhao S; Xu D
    Oncotarget; 2016 May; 7(22):31972-9. PubMed ID: 26934125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
    Casuscelli J; Becerra MF; Manley BJ; Zabor EC; Reznik E; Redzematovic A; Arcila ME; Tennenbaum DM; Ghanaat M; Kashan M; Stief CG; Carlo M; Voss MH; Feldman DR; Motzer RJ; Chen Y; Reuter VE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2019 Jul; 5(4):642-649. PubMed ID: 28951115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polypoid urothelial tumor with inverted growth pattern in the renal pelvis: morphologic and molecular characteristics of a unique diagnostic entity.
    Wobker SE; Zhong M; Epstein JI
    Hum Pathol; 2017 Jan; 59():26-33. PubMed ID: 27574810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
    Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
    Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations in clear cell renal cell carcinoma.
    Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
    Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTERT promoter methylation and single nucleotide polymorphism (-245 T>C) affect renal cell carcinoma behavior in Serbian population.
    Trifunovic J; Basta Jovanovic G; Nikolic N; Carkic J; Marjanovic A; Brankovic M; Radojevic Skodric S; Prvanovic M; Jovanovic A; Dzamic Z; Milasin J
    J BUON; 2018; 23(6):1887-1892. PubMed ID: 30610818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory region mutations of
    Xing X; Yuan X; Liu T; Dai M; Fan Y; Liu C; Strååt K; Björkholm M; Xu D
    J Cancer; 2021; 12(13):3853-3861. PubMed ID: 34093793
    [No Abstract]   [Full Text] [Related]  

  • 14. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma.
    Fang D; He S; Xiong G; Singla N; Cao Z; Zhang L; Li X; Zhou L
    BMC Urol; 2018 Mar; 18(1):22. PubMed ID: 29587736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging targets in upper tract urothelial carcinomas: the TERT gene.
    Ortíz Restrepo A; Ross JS; Spiess PE; Necchi A; Li R; García-Perdomo HA
    Can J Urol; 2022 Dec; 29(6):11378-11383. PubMed ID: 36495580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.